新型冠状病毒对人体系统影响的研究进展

doi:10.12183/j.scjpm.2024.0579

摘要/Abstract

摘要： 随着对新型冠状病毒认识的不断提高,新冠患者的急性症状得到有效改善,继急性感染期后长期持续的症状成为社会关注的焦点。世界卫生组织（WHO）对“长新冠（long COVID）”的定义是感染新型冠状病毒后3个月内发生,症状至少持续2个月,涉及全身多个系统,且无法由其他医学诊断解释。本研究就“长新冠”对呼吸系统、循环系统、神经系统和精神心理等产生的影响,包括发病机制和临床表现进行综述,意在提高对“长新冠”综合征的认识,为“长新冠”患者更好地康复提供思路。

中图分类号:

R181.3

李琳琳, 李程浩, 孙文玉, 郝世杰, 毕鸿雁, 李超. 新型冠状病毒对人体系统影响的研究进展[J]. 华南预防医学, 2024, 50(6): 579-582.

参考文献

[1] Walls AC,Park YJ,Tortorici MA,et al.Structure,function,and ntigenicity of the SARS-CoV-2 spike glycoprotein[J]. Cell,2020,181(2):281-292.
[2] Shang J,Ye G,Shi K,et al.Structural basis of receptor recognition by SARS-CoV-2]J]. Nature,2020,581(7807):221-224.
[3] Harmer D,Gilbert M,Borman R,et al.Quantitative mRNA expression profiling of ACE 2,a novel homologue of angiotensin converting enzyme[J].Febs Letters,2002,532(1-2):107-110.
[4] Soriano JB,Murthy S,Marshall JC,et al.A clinical case definition of post-COVID-19 condition by a Delphi consensus[J].Lancet Infect Dis,2022,22(4):e102-e107.
[5] Carfì A,Bernabei R,Landi F,et al.Persistent symptoms in patients after acute COVID-19[J]. JAMA,2020,324(6):603-605.
[6] Gattinoni L,Chiumello D,Caironi P,et al.COVID-19 pneumonia:Different respiratory treatments for different phenotypes?[J].Intensive Care Med,2020,46(6):1099-1102.
[7] Bai HX,Wang R,Xiong Z,et al.Artificial intelligence augmentation of radiologist performance in distinguishing COVID-19 from pneumonia of other origin at chest CT[J].Radiology,2020,296(3):E156-E165.
[8] Yasin R,Gomaa AAK,Ghazy T,et al.Predicting lung fibrosis in post-COVID-19 patients after discharge with follow-up chest CT findings[J].Egypt J Radiol Nucl Med,2021,52(1):118.
[9] Sudre CH,Murray B,Varsavsky T,et al.Attributes and predictors of Long-COVID:Analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App[J].Nat Med,2021,27(4):626-631.
[10] Chopra V,Flanders SA,O'Malley M,et al.Sixty-day outcomes among patients hospitalized with COVID-19[J]. Ann Intern Med,2021,174(4) :576-578.
[11] Huang Y,Tan C,Wu J,et al.Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase[J].Respir Res,2020,21(1):163.
[12] Singal CMS,Jaiswal P,Seth P .SARS-CoV-2,more than a respiratory virus:Its potential role in neuropathogenesis[J].ACS Chem Neurosci,2020,11(13):1887-1899.
[13] Calabrese F,Pezzuto F,Fortarezza F,et al.Pulmonary pathology and COVID-19:Lessons from autopsy. The experience of European pulmonary pathologists[J]. Virchows Arch,2020,477(3):359-372.
[14] Tian S,Xiong Y,Liu H,et al.Pathological study of the 2019 novel coronavirus disease (COVID-19) through post-mortem core biopsies[J]. Mod Pathol,2020,33:1007-1014.
[15] Cares-Marambio K,Montenegro-Jiménez Y,Torres-Castro R,et al.Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019(COVID-19):A systematic review and meta-analysis[J]. Chron Respir Dis,2021,18:1479973121100222240.
[16] Liang L,Yang B,Jiang N,et al.Three-month follow-up study of survivors of coronavirus disease 2019 after discharge[J].J Korean Med Sci,2020,35(47):418.
[17] Giustino G,Croft LB,Stefanini GG,et al.Characterization of myocardial injury in patients with COVID-19[J].J Am Coll Cardiol,2020,76(18):2043-2055.
[18] Bois MC,Boire NA,Layman AJ,et al.COVID-19-associated nonocclusive fifibrin microthrombi in the heart[J]. Circulation,2021,143(3):230-243.
[19] Vrints CJM,Krychtiuk KA,Van Craenenbroeck EM,et al.Endothelialitis plays a central role in the pathophysiology of severe COVID-19 and its cardiovascular complications[J]. Acta Cardiol 2021,76(2):109-124.
[20] Robinson FA,Mihealsick RP,Wagener BM,et al.Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection[J].Am J Physiol Heart Circ Physiol,2020,319(5):H1059-H1068.
[21] Yang L,Xie X,Tu Z,et al.The signal pathways and treatment of cytokine storm in COVID-19[J]. Signal Transduct Target Ther,2021,6(1):255.
[22] Hu Z,Li S,Song X.Cytokine storm with rapidly elevated interleukin-6 indicates sudden death in patients with critical COVID-19[J]. Cytokine Growth Factor Rev,2021,58:30-31.
[23] Wang D,Hu B,Hu C,et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan,China[J].JAMA,2020,323(11):1061-1069.
[24] Zhou F,Yu T,Du R,et al.Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan,China:A retrospective cohort study[J].Lancet ,2020,395(10229):1054-1062.
[25] Szekely Y,Lichter Y,Taieb P,et al.Spectrum of cardiac manifestations in COVID-19:A systematic echocardiographic study[J].Circulation,2020,142(4):342-353.
[26] Argulian E,Sud K,Vogel B,et al.Right ventricular dilation in hospitalized patients with COVID-19 infection[J].JACC Cardiovasc Imaging,2020,13(11):2459-2461.
[27] Puntmann VO,Carerj ML,Wieters I .Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)[J].JAMA Cardiol,2020,5(11):1265-1273.
[28] Weckbach LT,Curta A,Bieber S,et al.Myocardial inflammation and dysfunction in COVID-19-associated myocardial injury[J].Circ Cardiovasc Imaging,2021,14(1):e012220.
[29] Pezzini A,Padovani A.Lifting the mask on neurological manifestations of COVID-19[J]. Nat Rev Neurol,2020,16(11):636-644.
[30] Tsai LK,Hsieh ST,Chang YC.Neurological manifestations in severe acute respiratory syndrome[J]. Acta Neurol Taiwan,2005,14(3):113-119.
[31] Liotta EM,Batra A,Clark JR,et al.Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients[J]. Ann Clin Transl Neurol,2020,7(11):2221-2230.
[32] Lechien JR,Chiesa-Estomba CM,De Siati DR,et al.Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19):A multicenter European study[J].Eur Arch Otorhinolaryngol,2020,277(8):2251-2261.
[33] Beltrán-Corbellini Á,Chico-García JL,Martínez-Poles J,et al.Acute-onset smell and taste disorders in the context of COVID-19:A pilot multicentre polymerase chain reaction based case-control study[J]. Eur J Neurol,2020,27(9):1738-1741.
[34] Peyrony O,Marbeuf-Gueye C,Truong V,et al.Accuracy of emergency department clinical fifindings for diagnosis of coronavirus disease 2019[J]. Ann Emerg Med,2020,76(4):405-412.
[35] Struyf T,Deeks JJ,Dinnes J,et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease[J]. Cochrane Database Syst Rev,2020,7(7):CD013665.
[36] Tong JY,Wong A,Zhu D,et al.The prevalence of olfactory and gustatory dysfunction in COVID-19 patients:A systematic review and meta-analysis[J]. Otolaryngol Head Neck Surg,2020,163(1):3-11.
[37] Kanjanaumporn J,Aeumjaturapat S,Snidvongs K,et al.Smell and taste dysfunction in patients with SARS-CoV-2 infection:A review of epidemiology,pathogenesis,prognosis,and treatment options[J].Asian Pac J Allergy Immunol,2020,38(2):69-77.
[38] Frontera JA,Sabadia S,Lalchan R,et al.A prospective study of neurologic disorders in hospitalized COVID-19 patients in New York City[J].Neurology,2021,96(4):e575-e586.
[39] Pun BT,Badenes R,Heras La Calle G,et al.Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D):A multicentre cohort study[J]. Lancet Respir Med,2021,9(3):239-250.
[40] Agustín Sancho-Saldaa,Lambea-Gil L,Liesa JLC,et al.Guillain-Barré syndrome associated with leptomeningeal enhancement following SARS-CoV-2 infection[J].Clin Med (Lond),2020,20(4):e93-e94.
[41] Heneka MT,Golenbock D,Latz E,et al.Immediate and long-term consequences of COVID-19 infections for the development of neurological disease[J]. Alzheimers Res Ther,2020,12(1):69.
[42] Helms J,Kremer S,Merdji H,et al.Neurologic features in severe SARS-COV-2 infection[J].N Engl J Med,2020,382(23):2268-2270.
[43] Mazza MG,De Lorenzo R,Conte C,et al.Anxiety and depression in COVID-19 survivors:Role of inflflammatory and clinical predictors[J]. Brain Behav Immun,2020,89:594-600.
[44] Brooks SK,Webster RK,Smith LE,et al.The psychological impact of quarantine and how to reduce it:Rapid review of the evidence[J].Lancet,2020,395(10227):912-920.
[45] Aiyegbusi OL,Hughes SE,Turner G,et al.Symptoms,complications and management of long COVID:A review[J].J R Soc Med,2021,114(9):428-442.
[46] Fabrizi F,Alfieri CM,Cerutti R,et al.COVID-19 and acute kidney injury:A systematic review and meta-analysis[J].Pathogens,2020,9(12):1052.
[47] Mosleh H,Moradi F,Mehdizadeh M,et al.Health concerns regarding the effect of the COVID-19 pandemic on male fertility[J].Clin Exp Reprod Med,2021,48(3):189-193.
[48] Feng Q,Li L,Wang X .Identifying pathways and networks associated with the SARS-CoV-2 cell receptor ACE2 based on gene expression profiles in human tissues[J].Front Mol Biosci,2020,7:568954.
[49] Marks M,Marks JL .Viral arthritis[J].Clin Med (Lond),2016,16(2):129-134.
[50] Zacharias H,Dubey S,Koduri G,et al.Rheumatological complications of Covid-19[J].Autoimmun Rev,2021,20(9):102883.
[51] Sachdeva M,Gianotti R,Shah M,et al.Cutaneous manife stations of COVID-19:Report of three casesan dareview of literature[J].J Dermatol Sci,2020,98(2):75-81.